Yahoo
NasdaqGS - Nasdaq Real Time Price USD

Medpace Holdings, Inc. (MEDP)

670.86 +22.72 (+3.51%)
As of 12:52:42 PM EST. Market Open.
Trade MEDP on Coinbase
Chart Range Bar
Loading chart for MEDP
  • Previous Close 648.14
  • Open 648.80
  • Bid 685.29 x 100
  • Ask 620.00 x 100
  • Day's Range 648.26 - 672.43
  • 52 Week Range 373.00 - 693.97
  • Volume 75,001
  • Avg. Volume 257,434
  • Market Cap (intraday) 18.765B
  • Beta (5Y Monthly) 1.11
  • PE Ratio (TTM) 37.25
  • EPS (TTM) 18.01
  • Earnings Date Oct 21, 2026
  • Forward Dividend & Yield -- (0.00%)
  • 1y Target Est 651.31
  • Morningstar Rating Rating available with Stock Picks access

Medpace Holdings, Inc. provides clinical research-based drug and medical device development services in North America, Europe, Asia, South America, Africa, and Australia. The company offers a suite of services supporting the clinical development process from Phase I to Phase IV in various therapeutic areas. It provides clinical development services to the pharmaceutical, biotechnology, and medical device industries; and development plan design, coordinated central laboratory, project management, regulatory affairs, clinical monitoring, data management and analysis, pharmacovigilance new drug application submissions, and post-marketing clinical support services. In addition, the company offers bio-analytical laboratory services, clinical human pharmacology, imaging services, and electrocardiography reading support for clinical trials. Medpace Holdings, Inc. was founded in 1992 and is based in Cincinnati, Ohio.

www.medpace.com

6,600

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Recent News

View More

Performance Overview

Trailing total returns as of 11/3/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

MEDP
19.45%
S&P 500 (^GSPC)
10.74%

1-Year Return

MEDP
12.94%
S&P 500 (^GSPC)
10.64%

3-Year Return

MEDP
144.65%
S&P 500 (^GSPC)
73.94%

5-Year Return

MEDP
199.17%
S&P 500 (^GSPC)
62.66%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q3 FY26
Revenue 716M
Earnings 137.46M
Profit Margin 19.20%

Q4

FY25

Q1

FY26

Q2

FY26

Q3

FY26

0
200M
400M
600M
17.5%
18.0%
18.5%
19.0%

Analyst Insights

View More

Analyst Price Targets

370.00 Low
651.31 Average
670.86 Current
730.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 10/26/2026
Analyst BMO Capital
Rating Action Maintains
Rating Market Perform
Price Action Raises
Price Target 600 -> 670

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    18.24%

  • Return on Assets (ttm)

    18.71%

  • Return on Equity (ttm)

    117.88%

  • Revenue (ttm)

    2.84B

  • Net Income Avi to Common (ttm)

    517.82M

  • Diluted EPS (ttm)

    18.01

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    705.32M

  • Total Debt/Equity (mrq)

    29.31%

  • Levered Free Cash Flow (ttm)

    497.78M

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: